Archives of Neuroscience

Published by: Kowsar

Pharmacological Management of Neuropathic Pain: Current Trends and Possible Approaches

Anil Kumar 1 , * , Raghavender Pottabathini 1 , Archana Bhatnagar 2 , Sukant Garg 3 and Varun Gupta 1
Authors Information
1 Pharmacology Division, University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Study, Panjab University, Chandigarh, India
2 Department of Biochemistry, Panjab University, Chandigarh, India
3 Department of Pathology, Dr. Harvansh Singh Judge Institute of Dental Sciences and Hospital, Panjab University, Chandigarh, India
Article information
  • Archives of Neuroscience: January 2017, 4 (1); e28998
  • Published Online: August 23, 2016
  • Article Type: Review Article
  • Received: April 11, 2015
  • Revised: July 6, 2016
  • Accepted: August 1, 2016
  • DOI: 10.5812/archneurosci.28998

To Cite: Kumar A, Pottabathini R, Bhatnagar A, Garg S, Gupta V. Pharmacological Management of Neuropathic Pain: Current Trends and Possible Approaches, Arch Neurosci. 2017 ; 4(1):e28998. doi: 10.5812/archneurosci.28998.

Abstract
Copyright © 2016, Tehran University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnotes
References
  • 1. Merskey H, Bogduk N. Classification of Chronic Pain. 2012;
  • 2. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology. 2007; 68(15): 1178-82[DOI][PubMed]
  • 3. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007; 132(3): 237-51[DOI][PubMed]
  • 4. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014; 155(4): 654-62[DOI][PubMed]
  • 5. Backonja M, Woolf CJ. Future directions in neuropathic pain therapy: closing the translational loop. Oncologist. 2010; 15 Suppl 2: 24-9[DOI][PubMed]
  • 6. Baron R. Mechanisms of disease: neuropathic pain--a clinical perspective. Nat Clin Pract Neurol. 2006; 2(2): 95-106[DOI][PubMed]
  • 7. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010; 9(8): 807-19[DOI]
  • 8. Taylor BK. Spinal inhibitory neurotransmission in neuropathic pain. Curr Pain Headache Rep. 2009; 13(3): 208-14[PubMed]
  • 9. Yowtak J, Lee KY, Kim HY, Wang J, Kim HK, Chung K, et al. Reactive oxygen species contribute to neuropathic pain by reducing spinal GABA release. Pain. 2011; 152(4): 844-52[DOI][PubMed]
  • 10. Kovelowski CJ, Ossipov MH, Sun H, Lai J, Malan TP, Porreca F. Supraspinal cholecystokinin may drive tonic descending facilitation mechanisms to maintain neuropathic pain in the rat. Pain. 2000; 87(3): 265-73[DOI]
  • 11. Hanlon KE, Herman DS, Agnes RS, Largent-Milnes TM, Kumarasinghe IR, Ma SW, et al. Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain. Brain Res. 2011; 1395: 1-11[DOI][PubMed]
  • 12. Cohen SP, Mao J. Neuropathic pain: mechanisms and their clinical implications. BMJ. 2014; 348[DOI][PubMed]
  • 13. Tontodonati M, Ursini T, Polilli E, Vadini F, Di Masi F, Volpone D, et al. Post-herpetic neuralgia. Int J Gen Med. 2012; 5: 861-71[DOI][PubMed]
  • 14. Gupta R. Postherpetic Neuralgia-Pain Management: Essential Topics for Examinations. 2014; : 79-81
  • 15. Sansone RA, Sansone LA. Pain, pain, go away: antidepressants and pain management. Psychiatry (Edgmont). 2008; 5(12): 16-9[PubMed]
  • 16. Gao Y, Ning G, Jia WP, Zhou ZG, Xu ZR, Liu ZM, et al. Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China. Chin Med J (Engl). 2010; 123(22): 3184-92[PubMed]
  • 17. Barnet CS, Tse JY, Kohane DS. Site 1 sodium channel blockers prolong the duration of sciatic nerve blockade from tricyclic antidepressants. Pain. 2004; 110(1-2): 432-8[DOI][PubMed]
  • 18. Lavoie PA, Beauchamp G, Elie R. Tricyclic antidepressants inhibit voltage-dependent calcium channels and Na(+)-Ca2+ exchange in rat brain cortex synaptosomes. Can J Physiol Pharmacol. 1990; 68(11): 1414-8[PubMed]
  • 19. Reynolds IJ, Miller RJ. Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc. Brit J Clin Pharmaco . 1988; 95(1): 95-102[DOI]
  • 20. Shlay JC, Chaloner K, Max MB, Flaws B, Reichelderfer P, Wentworth D, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA. 1998; 280(18): 1590-5[PubMed]
  • 21. Berger A, Dukes E, Mercadante S, Oster G. Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain. Eur J Cancer Care (Engl). 2006; 15(2): 138-45[DOI][PubMed]
  • 22. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009; 122(10 Suppl)-32[DOI][PubMed]
  • 23. Saarto T, Wiffen PJ, Saarto T. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007; (4)[DOI][PubMed]
  • 24. Coluzzi F, Mattia C. Mechanism-based treatment in chronic neuropathic pain: the role of antidepressants. Curr Pharm Des. 2005; 11(23): 2945-60[PubMed]
  • 25. Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpaa ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010; 85(3 Suppl)-14[DOI][PubMed]
  • 26. Jackson KC. Pharmacotherapy for neuropathic pain. Pain Pract. 2006; 6(1): 27-33[DOI][PubMed]
  • 27. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992; 326(19): 1250-6[DOI][PubMed]
  • 28. Otto M, Bach FW, Jensen TS, Brosen K, Sindrup SH. Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial. Pain. 2008; 139(2): 275-83[DOI][PubMed]
  • 29. Lee YC, Chen PP. A review of SSRIs and SNRIs in neuropathic pain. Expert Opin Pharmacother. 2010; 11(17): 2813-25[DOI][PubMed]
  • 30. Jung AC, Staiger T, Sullivan M. The efficacy of selective serotonin reuptake inhibitors for the management of chronic pain. J Gen Intern Med. 1997; 12(6): 384-9[PubMed]
  • 31. Bomholt SF, Mikkelsen JD, Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology. 2005; 48(2): 252-63[DOI][PubMed]
  • 32. Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology. 2001; 57(9): 1583-8[PubMed]
  • 33. Pedersen LH, Nielsen AN, Blackburn-Munro G. Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain. Psychopharmacology (Berl). 2005; 182(4): 551-61[DOI][PubMed]
  • 34. Watson CP, Gilron I, Sawynok J, Lynch ME. Nontricyclic antidepressant analgesics and pain: are serotonin norepinephrine reuptake inhibitors (SNRIs) any better? Pain. 2011; 152(10): 2206-10[DOI][PubMed]
  • 35. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther. 2004; 311(2): 576-84[DOI][PubMed]
  • 36. Kajdasz DK, Iyengar S, Desaiah D, Backonja MM, Farrar JT, Fishbain DA, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther. 2007; 29 Suppl: 2536-46[DOI][PubMed]
  • 37. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013; 309(13): 1359-67[DOI][PubMed]
  • 38. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015; 14(2): 162-73[DOI]
  • 39. Sindrup SH, Tuxen C, Gram LF, Grodum E, Skjold T, Brosen K, et al. Lack of effect of mianserin on the symptoms of diabetic neuropathy. Eur J Clin Pharmacol. 1992; 43(3): 251-5[PubMed]
  • 40. Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol. 2012; 52(1): 6-17[DOI][PubMed]
  • 41. Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry. 1997; 154(12): 1760-2[DOI][PubMed]
  • 42. Sumpton JE, Moulin DE. Treatment of neuropathic pain with venlafaxine. Ann Pharmacother. 2001; 35(5): 557-9[PubMed]
  • 43. Lemoyne J. [Essential facial neuralgia therapy with dimethyl-dithio-hydantoin]. Concours Med. 1951; 73(6): 461-3[PubMed]
  • 44. Blom S. Trigeminal Neuralgia: Its Treatment with a New Anticonvulsant Drug (G-32883). Lancet. 1962; 279(7234): 839-40[DOI]
  • 45. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry. 2010; 81(12): 1372-3[DOI][PubMed]
  • 46. Backonja MM. Use of anticonvulsants for treatment of neuropathic pain. Neurology. 2002; 59(5, Suppl 2)-7[DOI]
  • 47. Carrazana E, Mikoshiba I. Rationale and Evidence for the Use of Oxcarbazepine in Neuropathic Pain. J Pain Symptom Manag. 2003; 25(5)-5[DOI]
  • 48. Beydoun A, Shaibani A, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study. Acta Neurol Scand. 2006; 113(6): 395-404[DOI][PubMed]
  • 49. Simpson DM, McArthur JC, Olney R, Clifford D, So Y, Ross D, et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology. 2003; 60(9): 1508-14[PubMed]
  • 50. Silver M, Blum D, Grainger J, Hammer AE, Quessy S. Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain. J Pain Symptom Manage. 2007; 34(4): 446-54[DOI][PubMed]
  • 51. Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology. 2001; 56(2): 184-90[PubMed]
  • 52. Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS. Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain. 2002; 96(3): 375-83[DOI]
  • 53. Wiffen PJ, Derry S, Moore RA, Wiffen PJ. Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2013; 3(12)[DOI][PubMed]
  • 54. Kochar DK, Rawat N, Agrawal RP, Vyas A, Beniwal R, Kochar SK, et al. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM. 2004; 97(1): 33-8[PubMed]
  • 55. Kochar DK, Garg P, Bumb RA, Kochar SK, Mehta RD, Beniwal R, et al. Divalproex sodium in the management of post-herpetic neuralgia: a randomized double-blind placebo-controlled study. Qjm. 2004; 98(1): 29-34[DOI]
  • 56. Agrawal RP, Goswami J, Jain S, Kochar DK. Management of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: a prospective double-blind randomized placebo-controlled study. Diabetes Res Clin Pract. 2009; 83(3): 371-8[DOI][PubMed]
  • 57. Wiffen PJ, Derry S, Lunn MPT, Moore RA, Derry S. Topiramate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2013; (8)[DOI][PubMed]
  • 58. Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol. 2006; 6(1): 108-13[DOI][PubMed]
  • 59. Devi P, Madhu K, Ganapathy B, Sarma G, John L, Kulkarni C. Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy. Indian J Pharmacol. 2012; 44(1): 51-6[DOI][PubMed]
  • 60. Dauri M, Faria S, Gatti A, Celidonio L, Carpenedo R, Sabato AF. Gabapentin and pregabalin for the acute post-operative pain management. A systematic-narrative review of the recent clinical evidences. Curr Drug Targets. 2009; 10(8): 716-33[PubMed]
  • 61. Engelman E, Cateloy F. Efficacy and safety of perioperative pregabalin for post-operative pain: a meta-analysis of randomized-controlled trials. Acta Anaesthesiol Scand. 2011; 55(8)[DOI]
  • 62. Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014; 19(6): 328-35[PubMed]
  • 63. Imani F, Rahimzadeh P. Gabapentinoids: gabapentin and pregabalin for postoperative pain management. Anesth Pain Med. 2012; 2(2): 52-3[DOI][PubMed]
  • 64. Singh D, Kennedy DH. The use of gabapentin for the treatment of postherpetic neuralgia. Clin Ther. 2003; 25(3): 852-89[DOI]
  • 65. Krumova EK, Zeller M, Westermann A, Maier C. Lidocaine patch (5%) produces a selective, but incomplete block of Adelta and C fibers. Pain. 2012; 153(2): 273-80[DOI][PubMed]
  • 66. Meier T, Wasner G, Faust M, Kuntzer T, Ochsner F, Hueppe M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain. 2003; 106(1): 151-8[DOI]
  • 67. Golzari SEJ, Soleimanpour H, Mahmoodpoor A, Safari S, Ala A. Lidocaine and Pain Management in the Emergency Department: A Review Article. Anesth Pain Med. 2014; 3(3)[DOI]
  • 68. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2006; (3)[DOI][PubMed]
  • 69. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006; 174(11): 1589-94[DOI][PubMed]
  • 70. Ong EC. Controlled-release oxycodone in the treatment of neuropathic pain of nonmalignant and malignant causes. Oncology. 2008; 74 Suppl 1: 72-5[DOI][PubMed]
  • 71. Watson PCN, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003; 105(1): 71-8[DOI]
  • 72. Ballantyne JC. Opioid analgesia: perspectives on right use and utility. Pain Physician. 2007; 10(3): 479-91[PubMed]
  • 73. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011; 14(2): 145-61[PubMed]
  • 74. Ossipov MH, Lai J, King T, Vanderah TW, Porreca F. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers. 2005; 80(2-3): 319-24[DOI][PubMed]
  • 75. Morley JS, Bridson J, Nash TP, Miles JB, White S, Makin MK. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial. Palliat Med. 2003; 17(7): 576-87[PubMed]
  • 76. Gagnon B, Almahrezi A, Schreier G. Methadone in the treatment of neuropathic pain. Pain Res Manag. 2003; 8(3): 149-54[PubMed]
  • 77. Hemati K, Zaman B, Hassani V, Imani F, Dariaie P. Efficacy of fentanyl transdermal patch in the treatment of chronic soft tissue cancer pain. Anesth Pain Med. 2015; 5(1): 22900[DOI][PubMed]
  • 78. Hemati K. The Incidence of Severe Diarrhea with Transdermal Fentanyl Patch: An Uncommon Event. J Clin Diagn Res. 2015; 9(6)[DOI]
  • 79. Duhmke RM, Cornblath DD, Hollingshead JRF, Dühmke RM. Tramadol for neuropathic pain. Cochrane Database Syst Rev. 2004; (2)[DOI][PubMed]
  • 80. Liang YC, Huang CC, Hsu KS. The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain. Neuropharmacology. 2007; 53(1): 169-77[DOI][PubMed]
  • 81. Vera G, Cabezos PA, Martin MI, Abalo R. Characterization of cannabinoid-induced relief of neuropathic pain in a rat model of cisplatin-induced neuropathy. Pharmacol Biochem Behav. 2013; 105: 205-12[DOI][PubMed]
  • 82. Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010; 17(9): 1113[DOI][PubMed]
  • 83. Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ. 2010; 182(14): 694-701[DOI][PubMed]
  • 84. Kahan M, Srivastava A, Spithoff S, Bromley L. Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations. Can Fam Physician. 2014; 60(12): 1083-90[PubMed]
  • 85. Wissel J, Haydn T, Muller J, Brenneis C, Berger T, Poewe W, et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial. J Neurol. 2006; 253(10): 1337-41[DOI][PubMed]
  • 86. Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain. 2008; 9(3): 254-64[DOI][PubMed]
  • 87. Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010; 110(2): 604-10[DOI][PubMed]
  • 88. Huggins JP, Smart TS, Langman S, Taylor L, Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain. 2012; 153(9): 1837-46[DOI][PubMed]
  • 89. Crowe MS, Leishman E, Banks ML, Gujjar R, Mahadevan A, Bradshaw HB, et al. Combined inhibition of monoacylglycerol lipase and cyclooxygenases synergistically reduces neuropathic pain in mice. Br J Pharmacol. 2015; 172(7): 1700-12[DOI][PubMed]
  • 90. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 2009; 6(4): 713-37[DOI][PubMed]
  • 91. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA. 2003; 290(13): 1757-62[DOI][PubMed]
  • 92. Shaibani AI, Pope LE, Thisted R, Hepner A. Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a double-blind, placebo-controlled, multicenter study. Pain Med. 2012; 13(2): 243-54[DOI][PubMed]
  • 93. Kvarnstrom A, Karlsten R, Quiding H, Emanuelsson BM, Gordh T. The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. Acta Anaesthesiol Scand. 2003; 47(7): 868-77[PubMed]
  • 94. Huge V, Lauchart M, Magerl W, Schelling G, Beyer A, Thieme D, et al. Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. Eur J Pain. 2010; 14(4): 387-94[DOI][PubMed]
  • 95. Zhou HY, Chen SR, Pan HL. TargetingN-methyl-D-aspartate receptors for treatment of neuropathic pain. Rev Clin Pharmacol. 2014; 4(3): 379-88[DOI]
  • 96. Dahi-Taleghani M, Fazli B, Ghasemi M, Vosoughian M, Dabbagh A. Effect of Intravenous Patient Controlled Ketamine Analgesiaon Postoperative Pain in Opium Abusers. Anesth Pain Med. 2014; 3(3)[DOI]
  • 97. Entezary SR, Farshadpour S, Alebouyeh MR, Imani F, Emami Meybodi MK, Yaribeygi H. Effects of preoperative use of oral dextromethorphan on postoperative need for analgesics in patients with knee arthroscopy. Anesth Pain Med. 2014; 4(1): 11187[DOI][PubMed]
  • 98. Campbell CM, Kipnes MS, Stouch BC, Brady KL, Kelly M, Schmidt WK, et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain. 2012; 153(9): 1815-23[DOI][PubMed]
  • 99. Ackerman LL, Follett KA, Rosenquist RW. Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. J Pain Symptom Manage. 2003; 26(1): 668-77[DOI]
  • 100. Semenchuk MR, Sherman S. Effectiveness of tizanidine in neuropathic pain: an open-label study. J Pain. 2000; 1(4): 285-92[DOI][PubMed]
  • 101. Solanki SL, Goyal VK. Neuraxial dexmedetomidine: wonder drug or simply harmful. Anesth Pain Med. 2015; 5(2): 22651[DOI][PubMed]
  • 102. Derry S, Rice ASC, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2013; (2)[DOI][PubMed]
  • 103. Intiso D, Basciani M, Santamato A, Intiso M, Di Rienzo F. Botulinum Toxin Type A for the Treatment of Neuropathic Pain in Neuro-Rehabilitation. Toxins (Basel). 2015; 7(7): 2454-80[DOI][PubMed]
  • 104. Yoon SH, Merrill RL, Choi JH, Kim ST. Use of botulinum toxin type A injection for neuropathic pain after trigeminal nerve injury. Pain Med. 2010; 11(4): 630-2[DOI][PubMed]
  • 105. Kharkar S, Ambady P, Venkatesh Y, Schwartzman RJ. Intramuscular botulinum toxin in complex regional pain syndrome: case series and literature review. Pain Physician. 2011; 14(5): 419-24[PubMed]
  • 106. Apalla Z, Sotiriou E, Lallas A, Lazaridou E, Ioannides D. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain. 2013; 29(10): 857-64[DOI][PubMed]
  • 107. Ghasemi M, Ansari M, Basiri K, Shaigannejad V. The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy. J Res Med Sci. 2014; 19(2): 106-11[PubMed]
  • 108. Han ZA, Song DH, Chung ME. Effect of subcutaneous injection of botulinum toxin A on spinal cord injury-associated neuropathic pain. Spinal Cord. 2014; 52 Suppl 1-6[DOI][PubMed]
  • 109. Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012; 11(7)[DOI][PubMed]
  • 110. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet. 2009; 374(9697): 1252-61[DOI]
  • 111. Eisenberg E, Suzan E. Drug combinations in the treatment of neuropathic pain. Curr Pain Headache Rep. 2014; 18(12): 463[DOI][PubMed]
  • 112. Amr YM. Multi-day low dose ketamine infusion as adjuvant to oral gabapentin in spinal cord injury related chronic pain: a prospective, randomized, double blind trial. Pain Physician. 2010; 13(3): 245-9[PubMed]
  • 113. Banihashem N, Hasannasab B, Esmaeili A, Hasannasab B. Addition of Intrathecal Magnesium Sulfate to Bupivacaine for Spinal Anesthesia in Cesarean Section. Anesth Pain Med. 2015; 5(3)[DOI]
  • 114. Porreca F, Lai J, Bian D, Wegert S, Ossipov MH, Eglen RM, et al. A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. Proc Natl Acad Sci U S A. 1999; 96(14): 7640-4[PubMed]
  • 115. Palygin O, Lalo U, Verkhratsky A, Pankratov Y. Ionotropic NMDA and P2X1/5 receptors mediate synaptically induced Ca2+ signalling in cortical astrocytes. Cell Calcium. 2010; 48(4): 225-31[DOI][PubMed]
  • 116. Albrecht PJ, Nalwalk JW, Hough LB. Efficacy of improgan, a non-opioid analgesic, in neuropathic pain. Brain Res. 2011; 1424: 32-7[DOI][PubMed]
  • 117. Costigan M, Latremoliere A, Woolf CJ. Analgesia by inhibiting tetrahydrobiopterin synthesis. Curr Opin Pharmacol. 2012; 12(1): 92-9[DOI][PubMed]
  • 118. Gilron I, Dickenson AH. Emerging drugs for neuropathic pain. Expert Opin Emerg Drugs. 2014; 19(3): 329-41[DOI][PubMed]
  • 119. Sato K, Yama K, Murao Y, Tatsunami R, Tampo Y. Epalrestat increases intracellular glutathione levels in Schwann cells through transcription regulation. Redox Biol. 2013; 2: 15-21[DOI][PubMed]
  • 120. Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, Davis MD, et al. Oral protein kinase c beta inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study 2. Retina. 2011; 31(10): 2084-94[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments